Financial Services -
Asset Management - NASDAQ - US
$ 158.895
1.65 %
$ 9.06 B
Market Cap
29.37
P/E
1. INTRINSIC VALUE
Balance Sheet
Hamilton Lane Incorporated
| Current Assets | 257 M |
| Cash & Short-Term Investments | 115 M |
| Receivables | 127 M |
| Other Current Assets | 16.1 M |
| Non-Current Assets | 1.01 B |
| Long-Term Investments | 632 M |
| PP&E | 95.4 M |
| Other Non-Current Assets | 286 M |
| Current Liabilities | 247 M |
| Accounts Payable | 4.5 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 243 M |
| Non-Current Liabilities | 504 M |
| Long-Term Debt | 275 M |
| Other Non-Current Liabilities | 229 M |
EFFICIENCY
Earnings Waterfall
Hamilton Lane Incorporated
| Revenue | 554 M |
| Cost Of Revenue | 201 M |
| Gross Profit | 352 M |
| Operating Expenses | 103 M |
| Operating Income | 249 M |
| Other Expenses | 21.7 M |
| Net Income | 227 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Hamilton Lane Incorporated
| Net Income | 227 M |
| Depreciation & Amortization | 8.19 M |
| Capital Expenditures | -11.1 M |
| Stock-Based Compensation | 12.1 M |
| Change in Working Capital | -42.4 M |
| Others | -143 M |
| Free Cash Flow | 110 M |
Wall Street Analysts Price Targets
Hamilton Lane Incorporated
Wall Street analysts predict an average 1-year price target for HLNE of $118 , with forecasts ranging from
a
low of
$78 to a high of $147 .
HLNE Lowest Price Target
Wall Street Target
78 USD
-50.91%
HLNE Average Price Target
Wall Street Target
118 USD
-25.58%
HLNE Highest Price Target
Wall Street Target
147 USD
-7.49%
4. DIVIDEND
ANALYSIS
0.42%
DIVIDEND YIELD
0.49 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Hamilton Lane Incorporated
Sold
0-3 MONTHS
1.63 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
5.94 M USD 1
Bought
0 USD 0
0-3 MONTHS
106 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 weeks ago
Feb 12, 2025
|
Sell 1.63 M
USD
|
Rogers Hartley R.
Executive Co-Chairman
|
- 10255
|
159 USD |
|
3 months ago
Nov 11, 2024
|
Bought
106 K USD
|
Delgado-Moreira Juan
Co-Chief Executive Officer
|
+ 525
|
201.81 USD |
|
11 months ago
Mar 07, 2024
|
Sell 5.94 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 55000
|
108 USD |
|
1 year ago
Aug 16, 2023
|
Sell 42.3 K
USD
|
Varma Atul
Senior Advisor
|
- 459
|
92.25 USD |
|
1 year ago
Mar 09, 2023
|
Sell 7.64 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 100000
|
76.41 USD |
|
2 years ago
Nov 07, 2022
|
Sell 16.8 K
USD
|
Graves Reynoldo Vann
Director
|
- 255
|
65.81 USD |
|
2 years ago
Aug 31, 2022
|
Bought
857 K USD
|
Delgado-Moreira Juan
Vice Chairman
|
+ 12351
|
69.35 USD |
|
3 years ago
Sep 10, 2021
|
Sell 967 K
USD
|
Rogers Hartley R.
Chairman
|
- 11487
|
84.15 USD |
|
3 years ago
Sep 10, 2021
|
Sell 5.21 M
USD
|
Delgado-Moreira Juan
Vice Chairman
|
- 61864
|
84.15 USD |
|
4 years ago
Mar 04, 2021
|
Sell 1.68 M
USD
|
Rogers Hartley R.
Chairman
|
- 19245
|
87.36 USD |
|
4 years ago
Mar 04, 2021
|
Sell 6.55 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 75000
|
87.36 USD |
|
4 years ago
Nov 13, 2020
|
Sell 25.2 K
USD
|
VARON LESLIE F
Director
|
- 337
|
74.87 USD |
|
4 years ago
Sep 04, 2020
|
Sell 5.26 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 75000
|
70.18 USD |
|
4 years ago
Jun 05, 2020
|
Sell 4.56 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 65000
|
70.09 USD |
|
5 years ago
Nov 22, 2019
|
Sell 556 K
USD
|
Devlin Tara
10 percent owner
|
- 10000
|
55.57 USD |
|
5 years ago
Sep 12, 2019
|
Sell 9 M
USD
|
Delgado-Moreira Juan
Vice Chairman
|
- 150000
|
60.01 USD |
|
5 years ago
Sep 12, 2019
|
Sell 4.71 M
USD
|
Rogers Hartley R.
Chairman
|
- 78456
|
60.01 USD |
|
5 years ago
Jun 05, 2019
|
Sell 200 K
USD
|
Kelly Michael John
10 percent owner
|
- 3792
|
52.79 USD |
|
5 years ago
Mar 14, 2019
|
Sell 2.28 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 50000
|
45.65 USD |
|
5 years ago
Mar 14, 2019
|
Sell 430 K
USD
|
Devlin Tara
10 percent owner
|
- 10000
|
43.04 USD |
|
6 years ago
Nov 14, 2018
|
Bought
795 K USD
|
Delgado-Moreira Juan
Vice Chairman
|
+ 21450
|
37.04 USD |
|
6 years ago
Nov 09, 2018
|
Sell 41.3 K
USD
|
VARON LESLIE F
Director
|
- 1070
|
38.61 USD |
|
6 years ago
Sep 17, 2018
|
Sell 1.33 M
USD
|
Rogers Hartley R.
Chairman
|
- 28087
|
47.26 USD |
|
6 years ago
Sep 17, 2018
|
Sell 4.73 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 100000
|
47.26 USD |
|
7 years ago
Mar 05, 2018
|
Sell 8.56 M
USD
|
Oakville Number 2 Trust
10 percent owner
|
- 250000
|
34.25 USD |
|
7 years ago
Mar 05, 2018
|
Sell 15.3 M
USD
|
Delgado-Moreira Juan
Managing Director
|
- 446315
|
34.25 USD |
|
7 years ago
Mar 06, 2017
|
Bought
44.8 K USD
|
Delgado-Moreira Juan
Managing Director
|
+ 2800
|
16 USD |
7. News
Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women's Health and Dermatology
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma's Board of Directors has unanimously recomm.
businesswire.com
- 1 week ago
Hamilton Lane Q3 Earnings: Slowing Momentum, But Shares Remain Expensive
Q3 results showed revenue up 34% year over year, coupled with strong overall profitability, both benefiting from higher incentive fees. Underlying growth in assets under management/advisement was muted, up just 6% year over year. While growth is expected to slowdown in the coming quarters, shares remain richly valued at 34.6 times earnings.
seekingalpha.com
- 2 weeks ago
Hamilton Lane Announces Pricing of Public Offering of Class A Common Stock
CONSHOHOCKEN, Pa. , Feb. 10, 2025 /PRNewswire/ -- Private markets asset management firm Hamilton Lane Incorporated (Nasdaq: HLNE) ("Hamilton Lane") today announced the pricing of an underwritten public offering by Hamilton Lane and a selling stockholder of 1,572,536 shares of Class A common stock, in the aggregate, for gross proceeds of approximately $252 million.
prnewswire.com
- 3 weeks ago
Market viewing tariffs as negotiating tactic right now, says Hamilton Lane's Hirsch
Erik Hirsch, Hamilton Lane Co-CEO, joins 'Fast Money' to talk the impact of tariffs on the market.
youtube.com
- 3 weeks ago
Hamilton Lane Announces Public Offering of Class A Common Stock
CONSHOHOCKEN, Pa. , Feb. 10, 2025 /PRNewswire/ -- Private markets asset management firm Hamilton Lane Incorporated (Nasdaq: HLNE) ("Hamilton Lane") today announced that it has commenced an underwritten public offering of 1,572,536 shares of Class A common stock, in the aggregate, to be sold by Hamilton Lane and a selling stockholder, subject to market and other conditions.
prnewswire.com
- 3 weeks ago
Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #cosettepharma--Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations.
businesswire.com
- 3 weeks ago
Hamilton Lane Closes Inaugural Venture Access Fund with Over $615 Million in Commitments, Exceeding Target Fund Size
The Fund features a high-quality venture portfolio targeting top-performing, oversubscribed funds and companies CONSHOHOCKEN, Pa. , Feb. 6, 2025 /PRNewswire/ -- Leading global private markets investment management firm Hamilton Lane (Nasdaq: HLNE) today announced the final close of its Venture Access Fund ("VAF" or "the Fund"), which successfully exceeded its target fund size, raising $615.3 million in commitments.
prnewswire.com
- 3 weeks ago
Hamilton Lane Incorporated (HLNE) Q3 2025 Earnings Conference Call Transcript
Hamilton Lane Incorporated (NASDAQ:HLNE ) Q3 2025 Earnings Conference Call February 4, 2025 11:00 AM ET Company Participants John Oh - Head of Shareholder Relations Erik Hirsch - Co-CEO Jeff Armbrister - CFO Conference Call Participants Ken Worthington - JPMorgan Alex Blostein - Goldman Sachs Michael Cyprys - Morgan Stanley Mike Brown - Wells Fargo Aidan Hall - KBW Operator Good morning, ladies and gentlemen, and welcome to the Hamilton Lane Fiscal Third Quarter 2025 Earnings Call. At this time, all lines are in a listen-only mode.
seekingalpha.com
- 3 weeks ago
Hamilton Lane (HLNE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Hamilton Lane (HLNE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
- 3 weeks ago
Hamilton Lane (HLNE) Tops Q3 Earnings and Revenue Estimates
Hamilton Lane (HLNE) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.71 per share a year ago.
zacks.com
- 3 weeks ago
HAMILTON LANE INCORPORATED REPORTS THIRD QUARTER FISCAL 2025 RESULTS, WITH MANAGEMENT & ADVISORY FEES GROWING BY 11% AND ASSETS UNDER MANAGEMENT GROWING BY 12% YEAR-OVER-YEAR
CONSHOHOCKEN, Pa. , Feb. 4, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (Nasdaq: HLNE) today reported its results for the third fiscal quarter ended December 31, 2024.
prnewswire.com
- 3 weeks ago
Cosette Pharmaceuticals Appoints Brad Leonard as Vice President, Generics Commercial Operation
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #commercial--Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. In this role, Brad will spearhead Cosette's generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets. “Cosette is in the midst of an exciting period of accelerated growth and portfolio e.
businesswire.com
- 4 weeks ago
8. Profile
Summary
Hamilton Lane Incorporated HLNE
COUNTRY
US
INDUSTRY
Asset Management
MARKET CAP
$ 9.06 B
Dividend Yield
0.42%
Description
Hamilton Lane Incorporated is an investment firm specializing in direct and fund of fund investments. It provides following services: separate accounts (customized to each individual client and structured as single client vehicles); specialized strategies (fund-of-funds, secondaries, co-investments, taft-hartley, distribution management); advisory relationships (including due diligence, strategic portfolio planning, monitoring and reporting services); and reporting and analytics solutions. For direct investments, the firm invests in early, mid and late venture, mature companies, growth equity, emerging growth, distressed debt, later stage, turnarounds, bridge financing, mezzanine financing, and buyouts in middle market companies. For fund of fund investments, it invests in mezzanine, venture capital, private equity, turnaround, secondary investments, real estate, and special situation funds. The firm invests in real estate investments. It also invest in technology, healthcare, education, natural resources, energy and essential consumer goods sectors, cleantech, and environment, community development, and financial empowerment. It invests in private equity markets in North America, Latin America, United States, Western Europe, Middle East, Africa, United Kingdom, Asia, Japan, and Australia. The firm prefer to invest $1 million to $100 million in companies. It prefers to have majority stake in companies. Hamilton Lane Incorporated was founded in 1991 and is based in Conshohocken, Pennsylvania with additional offices across Europe, North America, and Asia.
Contact
110 Washington Street, Conshohocken, PA, 19428
https://www.hamiltonlane.com
IPO
Date
March 1, 2017
Employees
700
Officers
Mr. Mario Lucio Giannini J.D.
Executive Co-Chairman
Mr. Erik R. Hirsch
Co-Chief Executive Officer & Member of the Board
Dr. Juan M. Delgado-Moreira C.F.A., Ph.D.
Co-Chief Executive Officer & Member of the Board
Mr. Jeffrey B. Armbrister
Chief Financial Officer
Ms. Lydia A. Gavalis J.D.
General Counsel
Mr. Thomas J. Kerr
Co-Head of Investments & Co-Head of Secondary Investments
Mr. Andrew Schardt
Vice Chairman, Head of Investment Strategy & Co-Head of Direct Equity
Mr. Hartley Raymond Rogers
Executive Co-Chairman
Ms. Andrea F. Kramer
Chief Operating Officer & Chief Risk Officer
Mr. Drew T. Carl CPA
MD & Chief Accounting Officer